Revolution Medicines to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference and the TD Cowen 44th Annual Health Care Conference.
Related news for (RVMD)
- Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer
- Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting
- Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants
- Revolution Medicines Announces Commencement of Public Offering of Common Stock